Effects of Cynaroside on Cell Proliferation, Apoptosis, Migration and Invasion Though the MET/AKT/mTOR Axis in Gastric Cancer
Overview
Chemistry
Molecular Biology
Affiliations
The Chinese medicine monomer cynaroside (Cy) is a flavonoid glycoside compound that widely exists in plants and has a variety of pharmacological effects, such as its important role in the respiratory system, cardiovascular system and central nervous system. Studies have reported that Cy has varying degrees of anticancer activity in non-small cell lung cancer, cervical cancer, liver cancer, esophageal cancer and other cancers. However, there are no relevant reports about its role in gastric cancer. The MET/AKT/mTOR signaling pathway plays important roles in regulating various biological processes, including cell proliferation, apoptosis, autophagy, invasion and tumorigenesis. In this study, we confirmed that Cy can inhibit the cell growth, migration and invasion and tumorigenesis in gastric cancer. Our finding shows that Cy can block the MET/AKT/mTOR axis by decreasing the phosphorylation level of AKT, mTOR and P70S6K. Therefore, the MET/AKT/mTOR axis may be an important target for Cy. In summary, Cy has anti-cancer properties and is expected to be a potential drug for the treatment of gastric cancer.
Sun S, Yu W, Zhang G, Li X, Song L, Lv Y Front Pharmacol. 2025; 16:1548672.
PMID: 40066330 PMC: 11891941. DOI: 10.3389/fphar.2025.1548672.
Flavonoids in the Treatment of Non-small Cell Lung Cancer via Immunomodulation: Progress to Date.
Liang M, Huang Y, Huang S, Zhao Q, Chen Z, Yang S Mol Diagn Ther. 2025; .
PMID: 40036006 DOI: 10.1007/s40291-025-00772-y.
Mechanistic insights into the role of traditional Chinese medicine in treating gastric cancer.
Chen Z, Yu T, Wang Y, Li J, Zhang B, Zhou L Front Oncol. 2025; 14:1443686.
PMID: 39906672 PMC: 11790455. DOI: 10.3389/fonc.2024.1443686.
Lin X, Yang P, Li X, Xu Z, Wu H, Hu S Oncol Lett. 2024; 29(2):76.
PMID: 39650229 PMC: 11622105. DOI: 10.3892/ol.2024.14822.
Zhao Y, Han J, Yang R, Wang S, Zhang K, Lu H Oncol Lett. 2024; 29(1):64.
PMID: 39619170 PMC: 11606006. DOI: 10.3892/ol.2024.14810.